Assessment of QTc Interval Prolongation and its Relationship withGlycemic Control in Diabetic Populations across Demographic andClinical Spectrums
Abstract
To assess the QTc Interval Prolongation and its Relationship with Glycemic Control in Diabetic Populations across Demographic and Clinical Spectrums.
This cross-sectional study was carried out with outpatients visiting the Department of Medicine at Quaid-e-Azam Medical College in Bahawalpur, from November 2022 to May 2023. It involved a total of 255 diabetic patients, encompassing both genders, aged between 40 and 70 years. The focus was on evaluating the prolonged QTc interval.
The mean age of the patients is 54.23 ± 9.49 years, the HbA1c level is 7.32 ± 0.449, and the mean QTc interval is 439.88 ± 14.795 milliseconds, respectively. Among the 255 diabetic patients studied, prolonged QTc was noted in 98 (38%) of them. The mean HbA1c level for patients with prolonged QTc is 7.40 ± 0.374 contrasting with a slightly lower mean of 7.27 ± 0.485 in patients without prolonged QTc. The statistical significance of this difference is underscored by a P value of 0.024.
In conclusion, our study of 255 diabetic patients, showed a high prevalence of prolonged QTc intervals, observed in 38% of the patients. The study highlighted a significant correlation between prolonged QTc intervals and HbA1c levels, particularly pronounced in specific demographic and clinical subgroups. Elevated HbA1c levels were more frequently associated with QTc prolongation, especially in younger patients (40-55 years) and those with dyslipidemia. However, the study found no significant difference in QTc prolongation between genders.
How to Cite This Article
Noor S, Saeed R, Khan S, Bilal MH, Nayyer N, Iqba J. Assessment of QTc Interval Prolongation and its Relationship withGlycemic Control in Diabetic Populations across Demographic andClinical Spectrums. J Pak Soc Intern Med. 2024;5(1):413–417. doi:10.70302/jpsim.v5i1.2412
Conflict of Interest
All authors declare no competing interests.
Funding
No specific funding was received for this research.
Funder information follows the Crossref Funder Registry standard.
References
- Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X,et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10(1):14790.
- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diab Res ClinPract. 2019;157(11):107843.
- Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, delCañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5(4):444-70.
- Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001; 44(2):S14-21.
- Grisanti LA. Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes. Front Physiol. 2018;9(11):1669.
- Scholte AJ, Schuijf JD, Delgado V, Kok JA, Bus MT, Maan AC, et al. Cardiac autonomic neuropathy in patients with diabetes and no symptoms of coronary artery disease: Comparison of 123I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability. Eur J Nucl Med Mol Imaging. 2010;37(8):1698–705.
- Khoharo HK, Qureshi F. Frequency of cardiac autonomic neuropathy in patients with Type 2 diabetes mellitus reporting at a teaching hospital of Sindh. J Coll Physicians Surg Pak. 2008;18(12):751–4.
- Ninkovic VM, Ninkovic SM, Miloradovic V, et al. Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes. ActaDiabetol. 2016; 53(5):737‐44.
- Sertbas Y, Ozdemir A, Sertbas M, Dayan A, Sancak S, Uyan C. The effect of glucose variability on qtc duration and dispersion in patients with type 2 diabetes mellitus. Pak J Med Sci. 2017;33(1):22-26.
- Lu Z, Luu Y, Ip J, Husain I, Lu M, Kim CK, Yang P, Chu D, Lin R, Cohen I, Kaell A. The risk of QTc prolongation in non-diabetic and Diabetic Patients taking tyrosine kinase inhibitors (TKIs)-a patient Safety Project at a private oncology practice. J Com Hospital Inter Med Pers. 2021;11(6):799-807.
- Noori NM, Teimouri A, Nakhaee-Moghadam M, Kasravi M. Evaluation of Electrocardiographic Parameters in Diabetes Mellitus Type I in Children and Adolescent. Int J Pediatr 2019; 7(9): 10057-66.
- Sivieri R, Veglio M, Chinaglia A, Scaglione P, Cavallo‐Perin P, Neuropathy Study Group of the Italian Society for the Study of Diabetes, Piemonte affiliate. Prevalence of QT prolongation in a type 1 diabetic population and its association with autonomic neuropathy. DiabMed. 1993;10(10):920-4.
- Yang XH, Su JB, Zhang XL, Zhao LH, Xu F, Wang XQ, Cheng XB. The relationship between insulin sensitivity and heart rate-corrected QT interval in patients with type 2 diabetes. DiabetolMetabSynd. 2017; DOI 10.1186/s13098-017-0268-3. doi:10.1186/s13098-017-0268-3
- Taubel J, Pimenta D. Considering the risk of QTc prolongation in patients with diabetes mellitus. J CardiolPract. 2022;22(8):1-10.
- Lafqih MB, Asbar H, Rafi S, El Mghari G, El Ansari N. Acquired prolonged QT interval in patients with Type 2 diabetes: Prevalence a risk factor. World JAdv Res Rev. 2023;17(1):088-092.
Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.